BLI Banque de Luxembourg Investments Invests $41.56 Million in Zoetis Inc. $ZTS

BLI Banque de Luxembourg Investments purchased a new position in shares of Zoetis Inc. (NYSE:ZTS) in the 4th quarter, HoldingsChannel.com reports. The firm purchased 328,774 shares of the company’s stock, valued at approximately $41,564,000. Zoetis accounts for about 1.2% of BLI Banque de Luxembourg Investments’ holdings, making the stock its 21st biggest position.

Several other large investors also recently modified their holdings of the stock. RFG Advisory LLC increased its stake in shares of Zoetis by 4.9% during the 4th quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock worth $215,000 after purchasing an additional 80 shares during the last quarter. YANKCOM Partnership increased its stake in shares of Zoetis by 3.5% during the 4th quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock worth $302,000 after purchasing an additional 81 shares during the last quarter. Beese Fulmer Investment Management Inc. increased its stake in shares of Zoetis by 2.4% during the 3rd quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company’s stock worth $537,000 after purchasing an additional 85 shares during the last quarter. Quest 10 Wealth Builders Inc. increased its stake in shares of Zoetis by 4.7% during the 4th quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock worth $240,000 after purchasing an additional 86 shares during the last quarter. Finally, Financial Engines Advisors L.L.C. increased its stake in shares of Zoetis by 4.4% during the 3rd quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock worth $299,000 after purchasing an additional 87 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Insider Activity

In related news, Director Michael B. Mccallister acquired 3,000 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was bought at an average cost of $77.76 per share, with a total value of $233,280.00. Following the acquisition, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. The trade was a 13.94% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Paul Bisaro acquired 2,000 shares of the company’s stock in a transaction dated Wednesday, May 13th. The shares were bought at an average cost of $75.88 per share, with a total value of $151,760.00. Following the completion of the acquisition, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. The trade was a 7.73% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought 11,650 shares of company stock worth $886,384 in the last three months. Corporate insiders own 0.22% of the company’s stock.

Zoetis Stock Down 0.8%

ZTS opened at $78.80 on Tuesday. The company has a fifty day moving average price of $99.76 and a 200-day moving average price of $115.24. The firm has a market capitalization of $33.03 billion, a P/E ratio of 13.07, a price-to-earnings-growth ratio of 1.24 and a beta of 0.75. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. Zoetis Inc. has a one year low of $72.38 and a one year high of $169.50.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter last year, the firm earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts expect that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Monday, July 20th. Zoetis’s payout ratio is 35.16%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on ZTS shares. Leerink Partners restated a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Citigroup reduced their price objective on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research note on Monday, May 18th. JPMorgan Chase & Co. reduced their price objective on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. William Blair reiterated an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Finally, Bank of America lifted their price objective on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday, February 13th. Six equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Zoetis has an average rating of “Hold” and an average target price of $133.92.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis received UK approval for Lenivia (izenivetmab), a long-acting osteoarthritis pain therapy for dogs, which could support future product sales and help offset some legal-related negativity. Zoetis (ZTS) Receives UK Approval for Long-Acting Osteoarthritis Pain Therapy Lenivia
• Neutral Sentiment: Multiple law firms, including Rosen Law Firm, Levi & Korsinsky, Glancy Prongay Wolke & Rotter, Robbins Geller, the Schall Law Firm, Bronstein Gewirtz & Grossman, and DJS Law Group, issued repeated reminders about the pending securities class action and the July 27 lead-plaintiff deadline. ROSEN, A LONGSTANDING LAW FIRM, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZTS
• Negative Sentiment: The class-action filings alleging securities-law violations and investor losses may increase legal costs, create headline risk, and keep pressure on Zoetis shares until more clarity emerges. Zoetis Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – ZTS

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.